India’s Semaglutide Market Braces for Generic Influx as Patents Expire
New Delhi – The expiration of key patents on semaglutide in India this month is poised to unleash a wave of generic competition, potentially disrupting the market for diabetes and weight-loss medications. Over 50 brands are lining up to launch generic versions of the blockbuster drug, currently marketed under brand names like Ozempic, Wegovy, and Rybelsus.
Patent Expiry and Market Dynamics
The final patent protecting semaglutide’s composition and delivery in India expired in March 2026, opening the door for domestic pharmaceutical companies to manufacture and market their own versions of the drug. Industry insiders predict a significant increase in competition, often described as a “slum of brands.”
Key Players and Regulatory Approvals
Several Indian pharmaceutical firms have already received regulatory clearances to launch generic semaglutide. Sun Pharma’s Noveltreat and Sematrinity have been approved, signaling the beginning of a broader rollout. Dr. Reddy’s Laboratories is also preparing to enter the market with its generic version, Obeda, aiming for a 60% price reduction. Sun Pharma has committed to not selling semaglutide drugs in India until Novo Nordisk’s patent expires, but will continue exports to countries where Novo Nordisk does not hold patents.
Legal Challenges and Patent Disputes
Novo Nordisk A/S, the original developer of semaglutide, has been actively defending its patent rights in India. In December 2025, the Delhi High Court heard a case brought by Novo Nordisk against Sun Pharma, seeking to restrain the company from manufacturing and selling semaglutide-based products. The court allowed Dr. Reddy’s Laboratories to export the products to overseas markets, a decision Novo Nordisk is currently challenging. A previous patent expired in September 2024, with the final key patent expiring this month.
Pricing and Market Impact
The current price of innovator brands like Wegovy and Ozempic ranges from ₹15,000 to ₹25,000 per month. The entry of generic manufacturers is expected to significantly lower prices, making the medication more accessible to a wider patient population. Industry estimates suggest a potential $6 billion opportunity for Indian generic drug makers.
Future Outlook
The Indian semaglutide market is set for substantial growth as generic competition intensifies. Canada and Brazil, with a combined $2 billion market for semaglutide, represent initial generic opportunities of around $500 million. The increased availability and affordability of semaglutide are expected to benefit patients managing type 2 diabetes and obesity in India and beyond.